Ayse Seda Yazgili

Ms. Ayse Seda Yazgili

Helmholtz Zentrum München, Munich, Bavaria, Germany
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2022 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
AZAlessandro Zambusi
Alessandro Zambusi
KNKlara Tereza Novoselc
Klara Tereza Novoselc
SHSaskia Hutten
Saskia Hutten
SKSofia Kalpazidou
Sofia Kalpazidou
CKChristina Koupourtidou
Christina Koupourtidou
JNJovica Ninkovic
Jovica Ninkovic

1 August 2020 in Cell Reports
Verified
Journal Article
Open access
TMThomas Meul
Thomas Meul
KBKorbinian Berschneider
Korbinian Berschneider
SSSabine Schmitt
Sabine Schmitt
CMChristoph H. Mayr
Christoph H. Mayr
LMLaura F. Mattner
Laura F. Mattner
SMSilke Meiners
Silke Meiners
The proteasome is the main proteolytic system for targeted protein degradation in the cell and is fine-tuned according to cellular needs. Here, we demonstrate that mitochondrial dysfunction and concomitant metabolic reprogramming of the tricarboxylic acid (TCA) cycle reduce the assembly and activity of the 26S proteasome. Both mitochondrial mutations in respiratory complex I and treatment with the anti-diabetic drug metformin impair 26S proteasome activity. Defective 26S assembly is reversible and can be overcome by supplementation of aspartate or pyruvate. This metabolic regulation of 26S activity involves specific regulation of proteasome assembly factors via the mTORC1 pathway. Of note, reducing 26S activity by metformin confers increased resistance toward the proteasome inhibitor bortezomib, which is reversible upon pyruvate supplementation. Our study uncovers unexpected consequences of defective mitochondrial metabolism for proteasomal protein degradation in the cell, which has important pathophysiological and therapeutic implications.

24 November 2025 in Nature
Verified
Journal Article
Open access
PDF file
MWMark White
Mark White
MMMegan L. Mills
Megan L. Mills
LMLaura M. Millett
Laura M. Millett
KGKathryn Gilroy
Kathryn Gilroy
YHYourae Hong
Yourae Hong
OSOwen Sansom
Owen Sansom
The colorectal epithelium is rapidly renewing, with remarkable capacity to regenerate following injury. In colorectal cancer (CRC), this regenerative capacity can be co-opted to drive epithelial plasticity. Although oncogenic MAPK signalling in CRC is common, with frequent mutations of both KRAS (40–50%) and BRAF (10%) 1 , inhibition of this pathway typically drives resistance clinically. Here, given the development of KRAS inhibitors and licensing of BRAF inhibitor combinations 2–4 , we have interrogated key mechanisms of resistance to these agents in advanced preclinical CRC models. We show that oncogenic MAPK signalling induces epithelial-state changes in vivo, driving adoption of a regenerative/revival stem-like population, whereas inhibition leads to rapid transcriptional remodelling of both Kras -mutant and Braf- mutant tumours, favouring a WNT-associated, canonical stem phenotype. This drives acute therapeutic resistance in Kras -driven and delayed resistance in Braf -driven models. Where plasticity is restrained, such as in early metastatic disease, or through targeting ligand-dependent WNT pathway Rnf43 mutations, marked therapeutic responses are observed. This explains the super response to BRAF + EGFR-targeted therapies previously observed in a BRAF–RNF43 co-mutant patient population, highlighting the criticality of cellular plasticity in therapeutic response. Together, our data provide clear insight into the mechanisms underpinning resistance to MAPK-targeted therapies in CRC. Moreover, strategies that aim to corral stem cell fate, restrict epithelial plasticity or intervene when tumours lack heterogeneity may improve therapeutic efficacy of these agents.

1 June 2021 in STAR Protocols
Verified
Journal Article
Open access
AYAyse Seda Yazgili
Ayse Seda Yazgili
TMThomas Meul
Thomas Meul
VWVanessa Welk
Vanessa Welk
NSNora Semren
Nora Semren
IKIlona E. Kammerl
Ilona E. Kammerl
SMSilke Meiners
Silke Meiners
This protocol describes an easy and reliable in-gel proteasome assay to quantify the activity and composition of different proteasome complexes in cells and tissues. The assay works well with limited amounts of total cell protein lysates. Although this assay is optimized specifically for the proteasome chymotrypsin-like activity, it can be expanded to other proteasome activities as well. Using antibodies that detect distinct proteasome subunits or regulators, we can determine the composition and relative quantity of active proteasome complexes.

20 August 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
AYAyse Seda Yazgili
Ayse Seda Yazgili
FEFrédéric Ebstein
Frédéric Ebstein
SMSilke Meiners
Silke Meiners
Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases. Several proteasome inhibitors are approved for treating hematological cancers. However, their side effects impede their efficacy and broader therapeutic applications. Therefore, understanding the biology of the different proteasome complexes present in the cell is crucial for developing tailor-made inhibitors against specific proteasome complexes. Here, we will discuss the structure, biology, and function of the alternative Proteasome Activator 200 (PA200), also known as PSME4, and summarize the current evidence for its dysregulation in different human diseases. We hereby aim to stimulate research on this enigmatic proteasome regulator that has the potential to serve as a therapeutic target in cancer.

15 February 2026 in Journal of Cell Science
Verified
Journal Article
Closed access
AYAyse Seda Yazgili
Ayse Seda Yazgili
GGGeorgia A. Giotopoulou
Georgia A. Giotopoulou
SBSabine J. Behrend
Sabine J. Behrend
FKFrauke Koops
Frauke Koops
VNVanessa Neiens
Vanessa Neiens
SMSilke Meiners
Silke Meiners
Proteasome activator 200 (PA200; also known as PSME4) is upregulated in non-small cell lung cancer (NSCLC) and linked to poor prognosis. We have previously demonstrated that the overexpression of PA200 in NSCLC is associated with immune evasion and reduced responsiveness to immune checkpoint inhibitors. The cell autonomous function of PA200 in cancer growth, however, has not been solved. We here demonstrate that deletion of PA200 in two distinct lung cancer cell lines induced cell-specific alterations in proteasome composition and activities with a minor direct impact on overall proteasome activity. Deficiency of PA200 in lung cancer cells did not consistently alter tumor cell growth in vitro and in vivo. However, we observed concerted inhibition of tumor cell migration and invasion with conserved downregulation of the integrin ITGB3 and transcriptional dysregulation of multiple cell adhesion and extracellular matrix regulators. Our transcriptome profiling revealed a striking disparity in the transcriptional response to PA200 deletion in the two lung cancer cell lines. Together with our PA200 interactome analysis that uncovered an unexpected cell-dependent profile of PA200-interacting proteins, our data indicate that the function of PA200 is cell specific and depends on the cellular context. In conclusion, we here demonstrate that PA200 cell-autonomously regulates the invasive capacities of tumor cells thereby potentially promoting lung cancer spread and metastasis formation. This mechanism might add to PA200-related immune evasion and contribute to the observed poor prognosis of individuals with PA200-overexpressing lung cancer.